Relja Maja, Telarović Srdana
Department of Neurology, Medical School, Zagreb University, KBC-Kispaticeva 12, 10000 Zagreb, Croatia.
J Neurol. 2004 Feb;251 Suppl 1:I12-4. doi: 10.1007/s00415-004-1104-x.
Despite the controversy regarding specific mechanism of botulinum toxin action in pain relief, clinical results suggest that botulinum toxin type A may be promising treatment options for patients with primary chronic headache. To investigate this, we included sixteen patients with chronic tension-type headache in a prospective double blind, placebo-controlled crossover study and thirty patients in an open-label long-term study. All of the patients showed reduced severity of headache, reduced pericranial muscle tenderness and increased headache-free days during botulinum toxin A treatment. Moreover, constant and cumulative trend of improvement was present during long-term study indicating better quality of life during botulinum toxin treatment. There is need for further placebo-controlled clinical studies to identify the optimal dose, optimal number and place of injection sites as well as optimal injection techniques.
尽管肉毒杆菌毒素缓解疼痛的具体作用机制存在争议,但临床结果表明,A型肉毒杆菌毒素可能是原发性慢性头痛患者有前景的治疗选择。为了对此进行研究,我们将16例慢性紧张型头痛患者纳入一项前瞻性双盲、安慰剂对照交叉研究,将30例患者纳入一项开放标签长期研究。所有患者在接受A型肉毒杆菌毒素治疗期间,头痛严重程度减轻、颅周肌肉压痛减轻且无头痛天数增加。此外,在长期研究中存在持续和累积的改善趋势,表明肉毒杆菌毒素治疗期间生活质量更好。需要进一步开展安慰剂对照临床研究,以确定最佳剂量、最佳注射次数和注射部位以及最佳注射技术。